US Patent

US8414921 — Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2028-07-21 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions that combine a dipeptidyl peptidase-4 inhibitor with metformin hydrochloride for treating Type 2 diabetes.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1036`	—	metformin-hydrochloride
`U-1036`	—	metformin-hydrochloride

Patent Metadata

Patent number: US8414921
Jurisdiction: US
Classification: Method of Use
Expires: 2028-07-21
Drug substance claim: No
Drug product claim: Yes
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.